Fifth, this study demonstrates that the cyclophilin inhibitor rencofilstat, but not other potent anti-HCV agents such as NS5A inhibitors or NS5B inhibitors, prevents HCC development 16 h post-HCV infection. Here, PPIB is linked to hepatocellular carcinoma.